Endocrinology, Vol 116, 952-957, Copyright © 1985 by Endocrine Society

ARTICLES

Parallel studies of His-DTrp-Ala-Trp-DPhe-Lys-NH2 and human pancreatic growth hormone-releasing factor-44-NH2 in rat primary pituitary cell monolayer culture

O Sartor, CY Bowers and D Chang

His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GH-RP-6) is a synthetic hexapeptide that specifically releases GH both in vivo and in vitro in pituitary incubates. In this study, for the first time, GH-RP-6 was studied in primary pituitary cell monolayer culture. Parallel studies were performed with human pancreatic GH-releasing factor-44 (hpGRF-44). Culture conditions optimal for GH-RP-6 were not optimal for hpGRF-44. Both peptides released GH in a dose- and time-dependent manner. In this assay system, the ED50 for GH-RP-6 was 9 nM, and the ED50 for hp-GRF-44 was 1.6 nM. Calcium-blocking agents inhibited the GH responses of both peptides as well as basal GH release. Pretreatment with GH-RP-6 decreased the subsequent response to both GH-RP-6 and hpGRF-44. hpGRF- 44 down regulated itself but not GH-RP-6. Rat sera potentiated the GH response of hpGRF-44 but not that of GH-RP-6. GH-RP-6 and hpGRF-44 GH responses were additive. These results suggest that GH-RP-6 and hpGRF- 44 stimulate GH release via different somatotroph receptors.

This article has been cited by other articles:

				W. Wei, X. Qi, J. Reed, J. Ceci, H.-Q. Wang, G. Wang, E. W. Englander, and G. H. Greeley Jr. Effect of chronic hyperghrelinemia on ingestive action of ghrelin Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R803 - R808. [Abstract] [Full Text] [PDF]

				X. Bonnefont, A. Lacampagne, A. Sanchez-Hormigo, E. Fino, A. Creff, M.-N. Mathieu, S. Smallwood, D. Carmignac, P. Fontanaud, P. Travo, et al. Revealing the large-scale network organization of growth hormone-secreting cells PNAS, November 15, 2005; 102(46): 16880 - 16885. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				A.-C. A. R. Pinto, M. R. D. Silva, M. R. Martins, E. Brunner, and A.-M. J. Lengyel Effects of Short-Term Glucocorticoid Deprivation on Growth Hormone (GH) Response to GH-Releasing Peptide-6: Studies in Normal Men and in Patients with Adrenal Insufficiency J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1540 - 1544. [Abstract] [Full Text]

				M. Korbonits, G. Kaltsas, L. A. Perry, P. Putignano, A. B. Grossman, G. M. Besser, and P. J. Trainer The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2489 - 2495. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				K. Hanew, A. Utsumi, A. Tanaka, H. Ikeda, and Y. Yokogoshi Secretory Mechanisms of Growth Hormone (GH)-Releasing Peptide-, GH-Releasing Hormone-, and Thyrotropin-Releasing Hormone-Induced GH Release in Patients with Acromegaly J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3578 - 3583. [Abstract] [Full Text]

				I. Shimon, X. Yan, and S. Melmed Human Fetal Pituitary Expresses Functional Growth Hormone-Releasing Peptide Receptors J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 174 - 178. [Abstract] [Full Text]